))
Professor Amit Nathwani’s journey to create a one-shot cure for haemophilia A
Manage episode 412999761 series 3438611
Indhold leveret af UCL Minds. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af UCL Minds eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
To mark World Haemophilia Day, we sit down with Professor Amit Nathwani of the UCL Cancer Institute to explore his journey to commercialising the groundbreaking haemophilia A treatment, Roctavian. Host Nigel Campbell is joined by Prof Nathwani and Dr. Rick Fagan, UCLB Director of Biopharm, to explore how Amit’s work looking after patients with haemophilia in the NHS instilled a mission to develop a 'one and done' vaccine type approach to the condition. Amit’s lab to market story, working with UCLB, led to the creation of Roctavian, a one-time gene therapy used for the treatment of adults with severe haemophilia A. The therapy, which was licensed to BioMarin Pharmaceutical Inc, received marketing approval in Europe in 2022 and US FDA approval in 2023, and is now available to patients commercially.
Date of episode recording: 2024-04-10T00:00:00Z
Duration: 00:23:58
Language of episode: English
Presenter: Nigel Campbell
Guests: Prof Amit Nathwani; Dr Rick Fagan
Producer: Nora Amin
Visit out website for the transcript: https://www.uclb.com/
13 episoder
Del
